文献速递心脑血管急症重症综合管理与镇静镇痛

Loberamisal治疗急性缺血性卒中:LAIS随机临床试验

Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-09-10
一句话结论在症状发作48小时内,静脉注射loberamisal 40mg每日一次共10天,可提高急性缺血性卒中患者90天完全功能结局比例。

LAIS为多中心、双盲、随机、安慰剂对照3期试验,纳入中国32家医院998例18-80岁、基线NIHSS 7-20、病前mRS≤1、症状发作48小时内的急性缺血性卒中患者。干预为静脉loberamisal 40mg或匹配安慰剂每日一次共10天,联合标准卒中治疗。主要终点90天mRS 0-1比例:loberamisal组69.7% vs 安慰剂组56.3%(RR 1.24,95%CI 1.12-1.36;RD 13.28%,95%CI 7.24%-19.32%)。不良事件与严重不良事件两组相近,全因死亡率1.2% vs 2.0%。

要点

  • 纳入标准:18-80岁急性缺血性卒中,基线NIHSS 7-20,病前mRS≤1,症状发作48小时内。
  • 干预:静脉loberamisal 40mg每日一次连续10天,联合标准卒中治疗;对照为匹配安慰剂。
  • 主要终点:90天mRS 0-1比例loberamisal组69.7%(350/502)vs 安慰剂组56.3%(279/495),RR 1.24(95%CI 1.12-1.36),RD 13.28%(95%CI 7.24%-19.32%)。
  • 安全性:不良事件87.8% vs 88.7%,严重不良事件8.6% vs 10.7%,全因死亡1.2% vs 2.0%。
  • 结论:在症状发作48小时内治疗的急性缺血性卒中患者中,loberamisal较安慰剂提高90天完全功能结局比例,需进一步研究验证及拓展人群。

适用人群与场景

  • 成人18-80岁急性缺血性卒中患者,基线NIHSS 7-20,病前mRS≤1,症状发作48小时内,来自中国32家医院。
  • 排除人群原文未提及。

诊断标准与关键阈值

  • 急性缺血性卒中诊断标准原文未提及。
  • 基线神经功能缺损程度采用NIHSS评分7-20分。
  • 病前功能状态采用mRS≤1分。
  • 治疗时间窗为症状发作48小时内。

处置流程与药物剂量

  • 第一步:筛选符合纳入标准的急性缺血性卒中患者(18-80岁,NIHSS 7-20,病前mRS≤1,症状发作48小时内)。
  • 第二步:在标准卒中治疗基础上,随机给予静脉loberamisal 40mg或匹配安慰剂,每日一次,连续10天。
  • 第三步:主要疗效评估为90天mRS 0-1(完全功能结局)。
  • 安全监测包括不良事件、严重不良事件和死亡率。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心、双盲、随机、安慰剂对照3期临床试验,中国32家医院,样本量998例随机,997例接受至少1剂并纳入主要分析(loberamisal组502例,安慰剂组495例)。
  • 人群特征:中位年龄64岁(IQR 57-71),女性33.7%,中位基线NIHSS 8分(IQR 7-9)。
  • 主要终点:90天mRS 0-1比例loberamisal组69.7%(350例)vs 安慰剂组56.3%(279例),RR 1.24(95%CI 1.12-1.36),RD 13.28%(95%CI 7.24%-19.32%)。
  • 关键次要终点:原文未提及。
  • 不良事件:loberamisal组87.8%(441例)vs 安慰剂组88.7%(439例);严重不良事件8.6%(43例)vs 10.7%(53例);全因死亡1.2%(6例)vs 2.0%(10例)。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT),3期。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文指出需进一步研究验证这些发现,并确定获益是否能扩展到更广泛的患者群体;其他局限原文未提及。

对床旁实践的改变

  • 对于符合LAIS纳入标准(18-80岁、NIHSS 7-20、病前mRS≤1、症状发作48小时内)的急性缺血性卒中患者,在标准卒中治疗基础上,可考虑静脉loberamisal 40mg每日一次共10天,以改善90天完全功能结局。
  • 适用人群应严格参照试验纳入标准;不适用于超出48小时时间窗、NIHSS<7或>20、病前mRS>1、年龄<18或>80岁的患者(原文未纳入这些人群)。
  • 常见陷阱:不能将研究方案剂量外推为所有卒中患者的通用推荐;需注意该结论需进一步研究验证,且原文未提供其他次要终点或亚组数据。

指南或共识出处

  • Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial(JAMA),试验注册号NCT06517173。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Effective neuroprotective and neuroreparative therapies for acute ischemic stroke remain limited. Loberamisal is a small-molecule compound that dually targets the postsynaptic density 95 (PSD-95) pathway and α2 γ-aminobutyric acid type α (α2-GABAA) receptor.

OBJECTIVE: To evaluate the efficacy and safety of intravenous loberamisal for improving functional outcomes in patients with acute ischemic stroke.

DESIGN, SETTING, AND PARTICIPANTS: The Loberamisal for Acute Ischemic Stroke (LAIS) trial was a multicenter, double-blind, randomized, placebo-controlled phase 3 clinical trial conducted at 32 hospitals in China. Adults aged 18 to 80 years with acute ischemic stroke, a baseline National Institutes of Health Stroke Scale score of 7 to 20, and no prestroke disability (modified Rankin Scale score, ≤1) who presented within 48 hours of symptom onset were enrolled between July 24, 2024, and December 7, 2024, with final follow-up on April 8, 2025.

INTERVENTIONS: Participants were randomly assigned (1:1) to receive intravenous loberamisal (40 mg) or matching placebo once daily for 10 consecutive days, in addition to standard stroke care.

MAIN OUTCOMES AND MEASURES: The primary outcome was achieving a full functional outcome at 90 days, defined as a modified Rankin Scale (mRS) score of 0 to 1. Safety outcomes included adverse events, serious adverse events, and mortality.

RESULTS: Among 998 randomized participants, 997 received at least 1 dose of the study drug and were included in the primary analysis (502 in the loberamisal group and 495 in the placebo group). The median age was 64 years (IQR, 57-71), 336 participants (33.7%) were women, and the median baseline NIHSS score was 8 (IQR, 7-9). At 90 days, 350 participants (69.7%) in the loberamisal group achieved an mRS score of 0 to 1 compared with 279 (56.3%) in the placebo group (relative risk, 1.24; 95% CI, 1.12-1.36; risk difference, 13.28%; 95% CI, 7.24%-19.32%). Adverse events occurred in 441 participants (87.8%) in the loberamisal group and 439 (88.7%) in the placebo group. Serious adverse events occurred in 43 participants (8.6%) in the loberamisal group and 53 (10.7%) in the placebo group. All-cause mortality occurred in 6 participants (1.2%) in the loberamisal group and 10 (2.0%) in the placebo group.

CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke treated within 48 hours of symptom onset, intravenous loberamisal, compared with placebo, resulted in a higher proportion of patients achieving full functional outcomes at 90 days. Further studies are needed to validate these findings and establish whether the benefits could extend to a broader patient population.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06517173.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Li S, Feng B, He D, et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial. JAMA. 2026. PMID: 42721021. doi:10.1001/jama.2026.16557

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。